Genovis to present data from mAbCHECK™ system on ASMS June 4.
The automated mAbCHECK™ technology allows researchers within the biopharma industry to rapidly obtain critical product quality data via a completely automated workflow. Researchers will no longer have to do manual sample handling, as every step will be handled automatically in very short time.
– We are exited to show data for the first time using the mAbCHECK™ technology, which utilizes our enzymes in a completely new setting. This first application proves that the system is able to rapidly generate important analytical results to our customers developing monoclonal antibodies for therapeutic use. The mAbCHECK platform will help us expand our customer base and the use of our enzyme within biopharma process development. We plan to accelerate the development of this technology and start beta testing together with customers this fall, says Fredrik Olsson, CEO of Genovis.
Additional information about mAbCHECK:
The mAbCHECK system is designed to sample a bioreactor and automatically digest and separate individual antibody subdomains for direct analysis by mass spectrometry or other technologies. The system is built on the VersAFLo liquid handling system from Capsenze adapted for use with Genovis enzyme. The first data presented at ASMS will show rapid glycan analysis of monoclonal antibodies and Fc-fusions proteins using Bruker UHR MaXis Mass Spectrometry. Glycan pattern is an important quality attribute that developers and producers of therapeutic antibodies need to monitor.
